“The new report from JAMA released today continues to suggest that the combination of estrogen and progesterone in Prempro is associated with a small but statistically significant increased risk of breast cancer when taken for extended periods. The study, whose initial results were released in 2002, suggested similar risks at that time. The new report does suggest an increased death rate from breast cancer in users vs. nonusers (0.03% vs 0.01% per year). The estrogen only arm of the study continues to show no increased risk for breast cancer and this very important fact is often overlooked by the media. Therefore not much has changed. Hormone replacement therapy continues to be an option only for menopausal symptom control at the lowest dose and for the shortest amount of time possible.”
Mark P. Hyde, M.D., F.A.C.O.G.